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Abstract
Angioedema is defined as localized and self-limiting edema of the subcutaneous
and submucosal tissue, due to a temporary increase in vascular permeability
caused by the release of vasoactive mediator(s). When angioedema recurs without
significant wheals, the patient should be diagnosed to have angioedema as a dis-
tinct disease. In the absence of accepted classification, different types of angioe-
dema are not uniquely identified. For this reason, the European Academy of
Allergy and Clinical Immunology gave its patronage to a consensus conference
aimed at classifying angioedema. Four types of acquired and three types of hered-
itary angioedema were identified as separate forms from the analysis of the litera-
ture and were presented in detail at the meeting. Here, we summarize the analysis
of the data and the resulting classification of angioedema.
Angioedema is defined as localized and self-limiting edema of
the subcutaneous and submucosal tissue, due to a temporary
increase in vascular permeability caused by the release of
vasoactive mediator(s). It frequently occurs as part of urti-
caria, which is characterized by two symptoms: wheals,
edema of superficial skin layers, and angioedema, edema of
deep skin layers (1). When angioedema recurs without
significant wheals, the patient should be diagnosed to have
angioedema as a distinct disease. Quincke, in his paper on
‘circumscribed edema’ that he called ‘angioneurotic edema’
(2), was the first author who considered angioedema to be a
separate entity. Because of that, angioedema is still frequently
referred to as Quincke edema. Shortly thereafter, Osler (3),
in his seminal paper ‘Hereditary angioneurotic edema’, gave
the first exhaustive description of an angioedema standing
as a specific nosology entity, which was later renamed
hereditary angioedema (HAE). In 1963, Donaldson and
Evans identified C1 inhibitor (C1-INH) deficiency as the
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genetic defect underlying the disease described by Osler (4).
Nine years later, Caldwell et al. (5) identified an angioedema
patient in whom the deficiency of C1-INH was not heredi-
tary, but acquired, related to a concomitant lymphosarcoma.
In subsequent years, angioedema research has been focused
at unraveling the pathophysiology of angioedema related to
C1-INH deficiency, eventually shown to be bradykinin-medi-
ated, a conclusion proven correct by the clinical response to
a specific antagonist (6). The advent in 1980 of angiotensin-
converting enzyme inhibitors (ACEI), which encompass
angioedema as a side-effect, changed the fate of this disease.
Even if this side-effect occurs in <1% of treated subjects, the
millions of people receiving an ACEI worldwide increased
the incidence of angioedema (7) and angioedema became the
second most common cause of hospitalization for allergic dis-
eases after asthma (8). In 2000, Bork et al. (9) described a
form of HAE without C1-INH deficiency further widening
the spectrum of angioedema types.
Thus, diagnosis of angioedema needs to be refined by the
specification of the type. In the absence of an accepted classi-
fication, different types of angioedema are not uniquely iden-
tified. For this reason, the European Academy of Allergy
and Clinical Immunology (EAACI) gave its patronage to a
consensus conference aimed at classifying angioedema. This
conference was held from September 30, 2012 to October 2,
2012 in Gargnano del Garda, Italy. Attendance was based
on the HAWK group of angioedema experts, established in
2010 to provide evidence-based recommendations for the
treatment for HAE (10). Four types of acquired and three
types of HAE were identified as separate forms from the
analysis of the literature and were presented in detail at the
meeting. Here, we summarize the analysis of the data and
the resulting classification of angioedema (Fig. 1).
Idiopathic histaminergic acquired angioedema (IH-AAE)
Continuous administration of an antihistamine stops disease
recurrences in a significant proportion of non-HAE patients,
and this angioedema can be defined as ‘histaminergic’. The
term implies a role for the cutaneous mast cell and/or the
blood basophil and suggests that bradykinin or other vasoac-
tive substances will not be predominantly released. Histamine
release suggests the possibility of an allergic cause and identi-
fying such causes is the starting point in the evaluation of
patients with angioedema. Allergy is suspected if the recur-
rence of symptoms is sequential related to an exogenous
stimulus and confirmed by a positive skin prick test and/or
detection of clinical significant specific IgE. Stimuli such as
Figure 1 Classification of angioedema without wheals.
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medication and/or foods, insect bites/stings or other environ-
mental allergens, or physical stimuli may be detected by an
experienced allergist: they are frequently involved in patients
with acute angioedema, but only in a minority with recurrent
attacks. Furthermore, an unequivocal causal relationship
between infection or autoimmune disease and angioedema is
frequently difficult to confirm. When allergy and other causes
have been ruled out and an etiology cannot be identified, the
histaminergic angioedema is defined to be idiopathic or spon-
taneous. A series of 929 consecutive patients with angioedem-
a without urticaria presenting over a 10-year period at a
large angioedema specialty center (11) identified 124 patients
(16%) where a specific factor could be identified (a food,
drug, insect bite, environmental allergen, or other physical
stimulus), 55 (7%) with autoimmune disease or infection, 85
(11%) being ACE inhibitor related, 197 (25%) suffering from
HAE, and 294 cases of idiopathic angioedema. Among the
latter 294 patients with unknown etiology, the vast majority
(254 or 87%) responded well to long-term antihistamines and
were thus classified as being idiopathic histaminergic.
In idiopathic angioedema that is histaminergic, patients by
definition respond to high-dose antihistamines used prophy-
lactically on a daily basis (12). However, the mechanism by
which histamine release is initiated in this disorder is
unknown.
Clinical presentation
Due to the lack of publications addressing the problem of
clinical presentation of this form of angioedema, the follow-
ing data have been derived by the discussion among experts.
IH-AAE develops rapidly reaching a maximum within 6 h;
precipitating factors are not identified; drug history is irrele-
vant to the angioedema; the face is mostly affected; gastroin-
testinal and laryngeal mucosa are spared and death due to
the angioedema has not been reported; there is no preferred
age for onset; attacks are prevented by antihistamine and
respond to corticosteroids and epinephrine as acute treat-
ment; family history for angioedema is negative; there are no
associated diseases.
Diagnosis
Major diagnostic tools include exclusion of causes of angioe-
dema when potentially present based on the clinical features:
causative agents associated autoimmune/infectious disease,
C1-INH deficiency, and mutation in factor XII. In the
absence of an algorithm specific for angioedema, we suggest
employing the guidelines for diagnosis of urticaria (1). If ana-
phylaxis is suspected, measurement of serum mast cell tryp-
tase; skin prick testing or specific IgE antibodies, can be
indicated; rheumatoid factor, antinuclear antibodies, C3/C4
complement levels, and C1q antibodies if connective tissue
disease or urticarial vasculitis is suspected. Screening for
infectious foci when no obvious cause of angioedema is
detectable is rarely helpful. In the only published study of
angioedema without urticaria (11), appropriate treatment for
a concomitant infection markedly improved the angioedema
in all patients with dental granuloma: three of five patients
with sinusitis and five of seven patients with urinary tract
infection. In two patients infected with Helicobacter pylori
who experienced gastroesophageal reflux, angioedema
improved after proper eradication therapy in one case
only.
In conclusion, IH-AAE seems to be the most common
form of angioedema. Some of its clinical and pathogenetic
features are similar to idiopathic recurrent urticaria. It is
diagnosed on clinical features, exclusion findings, and thera-
peutic response. Antihistamine and corticosteroids represent
the basic treatment.
Idiopathic nonhistaminergic acquired angioedema
This type of angioedema identifies nonfamilial, nonhereditary
forms in which known causes of angioedema have been
excluded as for IH-AAE, but recurrences persist upon anti-
histamine treatment. Search of the medical literature match-
ing the terms idiopathic, nonhistaminergic, and angioedema
provides just a few papers (11, 13–16). Nevertheless, experts
placed an effort in providing a definition of this angioedema
for the strong belief that it could encompass a distinct,
homogeneous group of patients. Cicardi et al. (12) first used
this term for describing a group of patients with angioedema:
these patients presented with remarkable response to tranexa-
mic acid given for prophylaxis. A similar favorable effect of
tranexamic acid was reported in another series of angioedema
patients with analogous characteristics, but defined as
‘sporadic idiopathic bradykinin angioedema’ (17). The term
‘bradykinin-mediated’ is sometimes substituted for ‘nonhist-
aminergic’ assuming that bradykinin mediates this angioe-
dema. Even if experts agree that bradykinin is involved in
InH-AAE, experimental evidence confirming this hypothesis
is still limited. Cugno et al. (18) showed that one patient with
InH-AAE had high levels of bradykinin in the venous blood
effluent from the swollen arm, while in a similar situation,
but with IH-AAE, bradykinin levels were normal. Additional
evidence supportive of bradykinin as the mediator in this sit-
uation comes from scattered case reports showing efficacy of
the bradykinin receptor antagonist icatibant in reverting
angioedema that is not responsive to antihistamine (19–21).
Until such findings are confirmed in a significant series of
patients, we prefer to maintain the term nonhistaminergic for
patients with angioedema not prevented by antihistamine.
Furthermore, at least in some patients with angioedema not
responsive to antihistamines, a role for vasoactive mediators
other than bradykinin, for example cysteinyl leukotrienes, pro-
staglandins, or platelet-activating factor, should be considered.
Clinical presentation
Only two series of patients, 40 Italian and 35 French, can be
found in the literature to be considered representative of
InH-AAE (11, 17). Analysis of the Italian and French case
lists shows a slightly higher frequency of male gender (1.35
and 1.5, respectively) and age of onset at 36 and 42 year old.
Nearly all patients reported a facial location; abdominal
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symptoms were present in <30% and upper airways’ involve-
ment in 35% and 26%. Invasive management (endotracheal
intubation) for upper airway edema was reported for a single
patient in the Italian group. The mean duration of symptoms
was below 48 h and the frequency of recurrences high, with
more than half of the patients needing continuous prophy-
laxis with tranexamic acid.
Diagnosis
The clinical history is the first step to diagnosis. In the
absence of laboratory testing or biomarkers, the evidence
supporting that histamine is not the putative mediator is
based on the patient’s negative response to continuous treat-
ment with antihistamines. Based on recent recommendations
for urticaria and angioedema (22), we can agree on the fact
that second-generation antihistamines (azelastine, bilastine,
cetirizine, desloratadine, ebastine, fexofenadine, levocetirizine,
loratadine, mizolastine, and rupatadine) at licensed doses rep-
resent the first approach for these patients. Up to four times
increase in doses can be employed prophylactically before
concluding that InH-AAE is the diagnosis.
Treatment
There is no conclusive evidence for an effective treatment for
attacks of idiopathic nonhistaminergic angioedema. Efficacy
of tranexamic acid has been reported in two case series, but
no detailed data are available (11, 17). Case reports indicate
that icatibant can relieve symptoms of angioedema in these
patients, whereas no data specifically report on the efficacy
of corticosteroids (19–21).
Most data on the prevention of idiopathic nonhistaminergic
angioedema refer to the use of tranexamic acid. Cicardi et al.
(12) showed that up to 3 g/day of tranexamic acid induced
complete (11/15) or partial (4/15) prevention of idiopathic
nonhistaminergic angioedema. These data were further
extended by Du-Thanh et al. (17) who showed that up to
90% of patients had complete or partial remission of angioe-
dema attacks while on tranexamic acid. For patients with
thrombophilia, in whom tranexamic acid is contraindicated,
alternative agents adapted from treatment for chronic urti-
caria such as cyclosporine and anti-IgE antibody (oma-
lizumab) can be considered, but experience is still limited (23).
The different responses of patients with InH-AAE to either
tranexamic acid or immunosuppressive, for example corticos-
teroids or cyclosporine, and biological agents such as oma-
lizumab clearly indicate the heterogeneity of this form of
angioedema with regard to mediators involved in its patho-
genesis. Further studies are needed to identify subgroups of
patients with InH-AAE to better define prevention and treat-
ment strategies.
Acquired angioedema related to angiotensin-
converting enzyme inhibitors (ACEI-AAE)
The inhibition of ACE, which is involved in the breakdown
of bradykinin to inactive peptides, results in elevated plasma
levels of bradykinin that further increase during ACEI-AAE
(24, 25). The suggestion that ACEI-AAE is bradykinin-medi-
ated is reinforced by evidence that genomic and plasma vari-
ability of proteins interfering with bradykinin catabolism is
associated with risk of ACEI-AAE (26–31).
Incidence
Analysis of large cohorts of hypertensive patients suggests
angioedema to occur in <0.5% of patients taking ACEI, but
3–4.5-fold more often in black than in Caucasian subjects
(32–36). A meta-analysis of clinical trials evaluating angioe-
dema as a side-effect, reported an incidence of angioedema
of 0.30% (95% CI 0.28–0.32) with ACEI, 0.11% (95% CI
0.09–0.13) with ARB, 0.13% (95% CI 0.08–0.19) with direct
renin inhibitors, and 0.07% (95% CI 0.05–0.09) with placebo
(37). Based on these data, there was an agreement among
experts that an ARB-related angioedema should not be
included as a specific form of angioedema.
Clinical symptoms
Acquired angioedema related to angiotensin-converting
enzyme inhibitors is more frequent in female than male
patients and in individuals over 65 years of age (32, 38). The
latency between the initiation of ACEI therapy and the onset
of symptoms can vary greatly from a few hours to several
years, but it is more likely to occur early after initiation of
ACEI therapy (34, 39–42).
Acquired angioedema related to angiotensin-converting
enzyme inhibitors usually localizes to the face, followed by
lips, eyelids, tongue, neck, and upper airways (43). ACEI-
induced gastrointestinal angioedema has rarely been reported
although underdiagnoses of this complication cannot be
excluded (44, 45). Deaths from laryngeal edema due to
ACEI-AE have been reported (43, 46, 47).
Diagnosis
There is no test specifically modified during ACEI-AAE, and
therefore, it is diagnosed upon onset of not otherwise
explained angioedema in patients taking ACEI.
Therapy of ACEI-AAE
To prevent ACEI-AAE recurrences, the drug should be
immediately discontinued. Surprisingly, ACEI withdrawal is
not 100% effective. Long-term follow-up of 111 patients with
ACE-AE demonstrated that after discontinuation from
ACEI, 51 patients (46%) had further recurrences of angioe-
dema with a frequency that was milder in 32 and remained
unchanged in 18 (48). The switch to a different antihyperten-
sive therapy, including an ARB, did not seem to influence
the relapse. On the other hand, continued use of ACEI in
spite of angioedema results in a marked increase in the inci-
dence of recurrent angioedema with serious morbidity (39,
40). The reason for persistence of angioedema after ACEI
withdrawal is not clear. It is possible to speculate that such
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patients are slow bradykinin ‘catabolizers’ and have ‘hidden’
InH-AAE disclosed by ACEI.
Pathophysiology suggests that bradykinin-targeted drugs,
licensed to treat HAE due to C1 inhibitor deficiency, could
be effective to reverse symptoms in ACEI-AAE (8, 49–52).
Due to the lack of efficacy of corticosteroids and epineph-
rine, some of them have been used off label in ACEI-AAE.
In an uncontrolled study, in 20 patients with ACEI-AAE,
icatibant led to a rapid and complete disappearance of
symptoms (mean 4.5 h) (53). A multicenter, double-blind
study with icatibant in 30 patients with ACEI-AAE (Clin
Trial Gov. No: NCT01154361) was completed, and the first
data are expected in 2014. Potential effect of C1-INH is
supported by published case reports (54–56). To verify
these initial positive observations and the efficacy of
kallikrein antagonist ecallantide, randomized studies are
planned (ClinicalTrials.gov Identifier: NCT01843530 and
NCT01036659).
When the course is fulminant despite drug therapy, or
airway obstruction remains impending, securing of airways is
indicated. Depending on the location of angioedema, differ-
ent forms of airway securement may be selected (57).
Acquired angioedema with C1 inhibitor deficiency
The nongenetic nature of acquired angioedema with C1
inhibitor deficiency (C1-INH-AAE) implies that no muta-
tions in C1-INH gene (SERPING1) and no family history of
angioedema can be associated with this disease. In the
absence of epidemiological studies, prevalence of C1-INH-
AAE in the general population is estimated to be 1 : 10 that
of the hereditary form, that is, around 1 : 500 000 (58).
Pathophysiology and associated diseases
Studies on plasma from patients with C1-INH-AAE indicate
consumption of C1-INH and classical pathway complement
components and, during attacks, activation of contact system
with release of bradykinin, which causes angioedema (59–63).
The lymphoproliferative disease, frequently found in these
patients, could directly contribute to the consumption of C1
and C1-INH (5, 64–66). Evidence that curing the associated
lymphoma could cure biochemical and clinical signs of an-
gioedema confirms that lymphoma can be responsible for
C1-INH-AAE (49, 67, 68).
Acquired angioedema with C1 inhibitor deficiency can be
caused by autoantibodies neutralizing C1-INH function
(50)-binding epitopes mapped around its reactive center
(51, 52, 69–73). Although initially identified as an indepen-
dent form of acquired C1-INH deficiency, large case series
demonstrated that C1-INH-AAE with autoantibodies and
with lymphoproliferative diseases largely overlaps and
should be considered the same disease (49, 74, 75). Other
conditions, mainly SLE, are reported in C1-INH-AAE,
which appears as a syndrome with different possible associ-
ations (76). However, 20 of the 180 cases reported in the
literature had no underlying disease associated with their
C1-INH-AAE.
Clinical presentation and diagnosis
Acquired angioedema with C1 inhibitor deficiency starts after
the age of 40 years in 94% of patients. Family history of an-
gioedema is never present. Angioedema predominantly
involves the face, tongue, uvula, and upper airways although
any place in the body can swell (77, 78). Gastrointestinal
swelling attacks are less common in C1-INH-AAE patients
compared to C1-INH-HAE patients (77, 78).
Plasma levels of C1-INH function below 50% of normal
are the confirmatory test when diagnosis of C1-INH-AAE is
suspected. Antigen levels of C1-INH are similarly reduced.
However, the presence of cleaved C1-INH may give appar-
ently normal C1-INH antigen in about 20% of patients (76,
79). Significant reduction in C4 plasma levels is almost
invariably present. In some patient, at disease onset, C1-INH
deficiency and consumption of complement components can
only be evident during angioedema attacks (80). The majority
(70% or more) of C1-INH-AAE patients have a low C1q lev-
els and anti-C1-INH antibodies (76). When clinical and bio-
chemical data are not clear-cut to exclude hereditary C1-INH
deficiency, genetic analysis to exclude SERPING1 mutations
may be necessary to confirm C1-INH-AAE.
C1-INH-AAE patients should have routine clinical testing
to rule out underlying limphoprolyferative and autoimmune
diseases and MGUS. Testing should include a CBC with
differential, sedimentation rate, C-reactive protein, serum
protein electrophoresis, urine analysis for light chain pro-
teins, and if there are peripheral blood abnormalities sugges-
tive of a concomitant disease, then bone marrow biopsy
should be performed to rule out malignancies (81).
Treatment
Treatment of C1-INH-AAE should consider the underlying
disease as well as the frequency and severity of angioe-
dema. Curing the underlying disease, when present, can
cure angioedema, and this option should be considered.
However, when the underlying disease does not per se
require treatment (as for slow-growing lymphoproliferative
diseases), taking into consideration the burden derived
from angioedema symptoms versus the toxicity of treat-
ment should always be considered in the decision-making
process. Symptomatic treatment for angioedema recurrences
can in fact be provided using bradykinin-targeted drugs. In
the absence of controlled trials, these treatments are used
off label in C1-INH-AAE.
Some case reports suggest the possibility to treat C1-INH-
AAE with rituximab, a recombinant monoconal antibody
that targets CD20 surface antigens on B cells (49, 67, 82–85).
Most of these cases had fewer and less severe attacks after
treatment, and some actually went into remission and experi-
enced no further attacks.
Treatment for angioedema symptoms in patients with C1-
INH-AAE has been performed with C1-INH replacement
therapy (86). The majority of patients respond positively, but
some may be resistant to this treatment due to an extremely
rapid catabolism of C1-INH (70). There are a few case
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reports on the use of C1-INH as prophylactic therapy: as for
on demand, there are patients who do not respond to this
treatment (67, 87). Efficacy of on demand subcutaneous icati-
bant, the antagonist of bradykinin receptor, has been
reported in a small series of patients, including some resistant
to plasma-derived C1-INH (88–91). Similar efficacy, but in a
very limited number of patients, is reported with the subcuta-
neous plasma kallikrein inhibitor ecallantide (92). Attenuated
androgens, effective in prophylaxis of hereditary C1-INH
deficiency, are less effective in C1-INH-AAE (77, 93). How-
ever, antifibrinolytic agents (i.e., tranexamic acid) tend to be
more effective in C1-INH-AAE than in the hereditary form
and experts recommend this as the drug of choice for attack
prophylaxis in C1-INH-AAE (76, 86).
Hereditary angioedema with C1 inhibitor deficiency
(C1-INH-HAE)
Hereditary angioedema with C1-INH deficiency (C1-INH-
HAE) is a rare disease with minimal prevalence varying
from 1.09/100 000 to 1.51/100 000 inhabitants (94–96) and
an estimated prevalence of 1/10 000–1/100 000 inhabitants
(97, 98).
Genetic defect and pathophysiology
C1-INH-HAE is due to mutations in one of the two alleles
of C1-INH gene, SERPING1. A few homozygous mutations
were described, mostly in patients with consanguineous par-
ents (99–101). Structural abnormalities of the SERPING1 in
patients with C1-INH-HAE are very heterogeneous (102–
105), with prevalence of de novo mutations around 25% of
cases (106, 107). The mutations described in C1-INH-HAE
are collected in large universal genetic databases (OMIM ID
106100, Human Gene Mutation Database 119041) and in a
database specific to this disease (http://hae.enzim.hu) (108).
Mutations in SERPING1 result in reduced plasma levels
of C1-INH and instability of the contact system with facili-
tated release of bradykinin, identified as the key mediator of
angioedema. Two phenotypic variants have been described
(109). Type I is characterized by a quantitative decrease in
C1-INH, which results in diminished functional activity
(C1-INH-HAE type I), and type II is characterized by
normal or high levels of C1-INH, which is dysfunctional.
Clinical presentation
C1-INH-HAE is clinically manifested by recurrent, localized
subcutaneous or submucosal edema lasting for 2–5 days. The
most commonly involved organs include the skin, upper
respiratory airways, and gastrointestinal tract. The clinical
expression is highly variable among the patients, from
asymptomatic cases to patients suffering from disabling and
life-threatening attacks with a demonstrated humanistic and
economic burden (110, 111). Almost all patients with C1-
INH-HAE present recurrences of abdominal pain caused by
temporary bowel obstruction because of mucosal edema (98,
112). It is common that patients with C1-INH-HAE undergo
unnecessary surgery misdiagnosing for surgical emergency a
gastrointestinal angioedema.
Diagnosis
Suspected with above-mentioned symptoms, diagnosis of
C1-INH-HAE needs laboratory confirmation (98). Patients
with C1-INH-HAE present with low C4, and to a lesser
extent low C2, because of consumption due to the activation
of the classical complement pathway lacking its physiologi-
cal inhibitor C1-INH. Measurement of C4 levels is used for
screening of C1-INH-HAE because it is decreased even in
between attacks and only exceptionally can be normal (113).
Diagnosis is confirmed by the evidence of plasma C1-INH
levels below 50% of the normal values (93). Based on the
relative frequency of the two phenotypic variants of C1-
INH-HAE, 15% of patients will have normal quantitative
plasma levels of C1-INH. For this portion of patients, diag-
nosis requires measurement of C1-INH activity in plasma.
Two methods (chromogenic or immunoenzymatic), based on
measurement of the capacity of plasma to inhibit the ester-
ase activity of a fix amount of C1s, are currently available
to measure C1-INH activity. Neither is routinely performed
in diagnostic laboratories (114). The chromogenic assay is
usually preferred due to higher positive predictive value
close to 100%. Blood samples for functional assay should
be cautiously taken and handled to avoid in vitro loss of
activity. Recently, an international collaborative study estab-
lished the WHO 1st international standards for C1-inhibitor,
plasma, and concentrate (115). It is suggested by experts
that diagnosis of C1-INH-HAE should be based on two
reduced readings of C4 and quantitative and/or functional
C1-INH, separated by 1–3 months (116). Use of low C4 lev-
els plus low C1-INH functional activity for the diagnosis of
C1-INH deficiency has a specificity of 98–100% and a nega-
tive predictive value of 96% (117, 118). Patients with
C1-INH-HAE usually do not consume C1 complex, and
reduction in plasma levels of C1q is rare in nonhomozygous
forms (99–101, 119, 120).
Genetic testing is needed during the first year of age, when
C1-INH plasma levels may be falsely low and to distinguish
C1-INH-AAE when diagnosis is not clear-cut (116). Hetero-
geneity of mutations responsible for C1-INH-HAE makes
genetic diagnosis relatively complicated.
Treatment
Treatment of patients with C1-INH-HAE is aimed at avoid-
ing mortality and reducing morbidity. As morbidity is func-
tion of frequency and severity of attacks and mortality of
progression of laryngeal edema, effective treatments should
prevent and/or revert angioedema symptoms. Several drugs,
tested in double-blind placebo-controlled studies, detain such
an efficacy and are available, with differences from country to
country (Table 1) (6, 121–128). Several international consen-
sus papers, released since 2004, guide the treatment of
C1-INH-HAE, and here, we will provide just the general prin-
ciples derived from these guidelines (10, 116, 129–132). After
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being diagnosed as C1-INH-HAE, all patients should have
readily available, a drug of proved efficacy in reverting
attacks. Control of the disease should first be attempted
administering this drug as soon as the patient realizes that
angioedema symptoms start to develop. To have timely inter-
vention, it is highly recommended that patients are trained to
home treatment for either subcutaneous or intravenous
administration (132). If this approach does not reduce the
burden of the disease with significant improvement of the
quality of life, continuous prevention treatment should be
considered. Antifibrinolytic agents, attenuated androgens, and
plasma-derived C1-INH are available for this approach.
Although their efficacy had been proved in controlled studies,
antifibrinolytics are now rarely used for prophylaxis due a
reduced efficacy compared to the other two products (133).
Risk/benefit balance of starting long-term prophylaxis and the
product to use for this purpose should always be carefully
evaluated and individualized to each single patient (10, 116).
A final approach to treat patients with C1-INH-HAE is to
prevent attacks on a short term. This approach is mainly
addressed to avoid angioedema complications of medical
maneuvers, namely oral procedures that may trigger upper
airways edema. Specific indications present in therapeutic
consensus documents are derived from expert opinion and
uncontrolled series of patients (134–136). Plasma-derived C1-
INH, given at doses effective for on demand and as close as
possible to the procedure, appears as the most rational
approach because it is promptly effective and has a sufficient
half-life (116, 137, 138).
Hereditary angioedema with normal C1 inhibitor and
factor XII mutation (FXII-HAE) and of unknown origin
(U-HAE)
In 1985, a large family in which five women suffered from
recurrent angioedema of the skin associated with relapsing
episodes of abdominal pain attacks and episodes of upper
airway obstruction was observed (9). Surprisingly, all of the
women had normal C1-INH function. In 2000, this family
and nine additional families with similar symptoms and a
normal C1-INH function were identified (9). Interestingly,
in these 10 families, a total of 36 women, but not a single
man, were affected. In this initial description, the terms
‘hereditary angioedema with normal C1-INH’ or ‘hereditary
angioedema type III’ were proposed. Through 2003, all the
patients described in the literature were women, and there-
fore, it was assumed that the clinical phenotype might be
limited to the female sex (139–141). However, in 2006, a
family with dominantly inherited angioedema and normal
C1-INH was described in which not only five female but
also three male family members were clinically affected
(142).
Factor XII genetic defect
In May 2006, genetic mutations in six index patients of 20
families and in 22 patients of the corresponding six families
were identified: two different missense mutations have beenT
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verified which were assumed to be the cause of the disease
according to the co-segregation pattern of mutations and
the clinical symptoms in women (143). The location of these
mutations was the same locus, 5q33-qter as the Hageman
factor, or coagulation F12 gene (Online Mendelian Inheri-
tance in Man # 610619). One mutation leads to a threo-
nine-to-lysine substitution (Thr328Lys) and the other to a
threonine-to-arginine substitution (Thr328Arg). Both of
these mutations were located on the exon 9. It was also
found that the index patients of 14 further families with
HAE and normal C1-INH did not show these mutations
(143). More recently, a large deletion of 72 base pairs
(c.971_1018 + 24del72) and a duplication of 18 base pairs
(c.892_909dup) both located in the same region of F12 have
been described (144, 145). At present, we have patients with
HAE with normal C1-INH and mutation in the F12 gene
and patients with normal C1-INH and unknown genetic
defect (146–150). Hence, for patients with family history of
angioedema and normal C1-INH, we propose to use the
term factor XII-HAE (FXII-HAE) when mutation in F12
gene can be detected and unknown HAE (U-HAE) when
no genetic defect can be identified. FXII-HAE should be
used also for patients carrying mutations in the coagulation
F12 gene even when family history of angioedema is not
present, as family studies showed that angioedema symp-
toms segregate with the mutations (143). It is further
recommended that the term HAE type III no longer be
used, because HAE type I and II identify two specific types
of C1-INH deficiency.
Clinical presentation
Because many case lists of HAE and normal C1-INH were
presented as HAE type III before FXII-HAE subgroup was
identified, separating the characteristics of U-HAE from
FXII-HAE is difficult. Sex prevalence in U-HAE is not
clearly reported, while almost just women are affected with
FXII-HAE. F12 gene mutations are transmitted as an auto-
somal dominant trait with low penetrance: asymptomatic
carriers are >90% in male gender and around 40% in
female (146, 149, 150). The clinical symptoms include recur-
rent skin swellings, abdominal pain attacks, tongue swelling,
and upper airways edema. No difference in clinical symp-
toms due to the presence of F12 gene mutations has been
identified (146, 147, 151). Urticaria does not occur at any
time in any of these patients. The skin swellings typically
last 2–5 days; they affect mainly the extremities and the
face. The abdominal attacks likewise last 2–5 days and are
manifested as severe crampy pain. In a comprehensive
study, 138 patients with U-HAE/FXII-HAE from 43 unre-
lated families were examined (146). A majority of patients
had symptoms of skin swelling (92.8%), tongue swelling
(53.6%), and abdominal attacks (50%). Laryngeal edema
(25.4%) and uvular edema (21.7%) also were frequent,
whereas edema episodes of other organs were rare (3.6%).
In many women, the clinical symptoms were provoked
by oral contraceptives, hormonal replacement therapy, or
pregnancy.
Diagnosis
Diagnosis of U-HAE is purely based on clinical findings and
requires that patients have the (i) above-mentioned clinical
symptoms, (ii) one or more family members also affected
with these symptoms, (iii) the exclusion of familial and hered-
itary chronic urticaria with urticaria-associated angioedema,
(iv) normal C1-INH activity and protein in plasma, and (v)
no HAE-associated mutation in F12 gene. FXII-HAE has
analogous clinical criteria, but with the presence of an HAE-
associated mutation in F12 gene, which may also identify
solitary cases.
The laboratory diagnosis of FXII-HAE is purely genetic,
while there are no confirmatory laboratory tests for U-HAE.
The existence of sporadic cases of U-HAE can be assumed,
but not confirmed for the moment as such a diagnosis is
solely based on family history of angioedema.
Therapeutic approach
Patients with U-HAE/FXII-HAE do not respond to corticos-
teroids and antihistamines (152). Based on the presumed
pathophysiology, several potential treatment options are
available for U-HAE/FXII-HAE, including C1-INH agents,
icatibant, ecallantide, progesterone, danazol, and tranexamic
acid. However, there are no published controlled studies
using any of these novel therapies in these patients.
Final Consensus
Angioedema identifies recurrent edema caused by the release
of one of several existing vasoactive mediators. When angioe-
dema arises together with wheals, these patients with recur-
rent angioedema and wheals should be diagnosed as having
urticaria.
Statement 1: Angioedema is diagnosed when a patient
presents with recurrent angioedema symptoms in the absence
of wheals
Angioedema can be differentiated based on specific character-
istics. The discussion among experts suggested first distin-
guishing hereditary from nonhereditary forms. Angioedema
should be considered hereditary in the presence of a specific
risk factor for transmission to offspring. Identified risk fac-
tors supporting a diagnosis of HAE are as follows.
Statement 2: Angioedema is defined as hereditary when (i)
there is family history of angioedema within a second-degree
relative; (ii) there is a mutation in the SERPING1 or the F12
gene that has been demonstrated to be associated with
angioedema; and (iii) there is a familial deficiency of C1-
INH. All other forms of angioedema should be considered as
acquired
Based on the present knowledge, experts distinguished seven
specific forms of angioedema within the two categories of
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acquired and hereditary. Characteristics for diagnosis are
reported in Table 2.
Statement 3: Angioedema should be diagnosed as follows:
1 Acquired
1.1 Idiopathic histaminergic acquired angioedema (IH-
AAE)
1.2 Idiopathic nonhistaminergic acquired angioedema
(InH-AAE)
1.3 Acquired angioedema related to angiotensin-convert-
ing enzyme inhibitor (ACEI-AAE)
1.4 Acquired angioedema with C1-INH deficiency (C1-
INH-AAE)
2 Hereditary
2.1 Hereditary angioedema with C1-INH deficiency (C1-
INH-HAE)
2.2 Hereditary angioedema with FXII mutation (FXII-
HAE)
2.3 Hereditary angioedema of unknown origin (U-HAE)
Drugs approved to treat angioedema are limited to C1-
INH-HAE; their use in the other forms is off label. Specific
indications are reported in Table 3.
Table 2 Characteristics of different forms of angioedema
Acquired Hereditary
IH-AAE InH-AAE ACEI-AAE C1-INH-AAE C1-INH-HAE FXII-HAE U-HAE
Peripheral AE + ++ (11, 17) + (54) ++ (77, 78) +++ (98, 112) ++ (146, 150) +++ (146, 150)
Facial AE +++ ++ (11, 17) +++ (54) +++ (77, 78) ++ (98, 112) ++ (146, 150) ++ (146, 150)
Abdominal AE  + (11, 17) + (49, 50, 54) ++ (77, 78) +++ (98, 112) +++ (146, 150) +++ (146, 150)
Upper
respiratory AE
+ ++ (11, 17) +++ (51, 54) +++ (77, 78) +++ (98, 112) +++ (146, 150) +++ (146, 150)
Age at onset Any Any >65 (58) >40 <20 <30 <30
Speed of onset <6 12 12 (70) 24 24–36 24–36 24–36
Duration <24 h 24–48 12–48 (70) 36–72 36–72 36–72 36–72
Male/Female 1 : 1 1 : 1 2 : 1(46, 58) 1 : 1 1 : 1 10 : 1 1 : 1
Ethnic
predilection
Unknown Unknown Black (54, 56, 57) None None German/French/
Spanish
Unknown
Diagnostic
characteristic
Unidentified
etiology,
prevented by
antihistamine
Unidentified
etiology,
Nonprevented
by antihistamine
Onset while on
ACEI treatment
(9, 48, 53–55)
Nongenetic
C1-INH
deficiency
Genetic
C1-INH
deficiency
Angioedema-
associated
mutation in
FXII gene
Familial
angioedema
without
identified
genetic marker
Based on experts’ opinion and reference reported in brackets.
Table 3 Evidence for treatment efficacy in different forms of angioedema
Acquired Hereditary
IH-AAE InH-AAE ACEI-AAE C1-INH-AAE C1-INH-HAE FXII-HAE U-HAE
Antihistamine
prophylaxis
Prevention None None None None None None
C1 inhibitor
acute
None None Case report
(76–78)
Case list
(70, 86)
Controlled
studies (121, 126–128)
Case
reports (152)
Case
reports (152)
C1 inhibitor
prophylaxis
None None NA Case list
(67, 87)
Controlled
studies (126, 127)
Case
reports (152)
Case
reports (152)
Icatibant acute None Case
report
(19–21)
Case list
(75)
Case list
(88–91)
Controlled
studies (6)
Case
reports (152)
Case
report (150)
Ecallantide
acute
None None None Case
reports (92)
Controlled
studies (122)
None None
Att. Androgen
prophylaxis
None None NA Case list
(77, 93)
Controlled
studies (124)
Case
report (152)
Case
report (152)
Antifibrinolytic
prophylaxis
None Case list
(11, 17)
NA Case list (86) Controlled
studies (123, 125)
Case
reports (150)
Case
reports (150)
Based on experts’ opinion and references reported in brackets.
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Statement 4: licensed therapy of angioedema is limited to
C1-INH-HAE. Other forms can just be treated off label based
on small noncontrolled studies and expert experience
In conclusion, the present knowledge allows recognizing an-
gioedema as a separate nosology entity, which is comprised
of different forms that can be diagnosed based on specific
criteria. The absence of studies on angioedema, other than
C1-INH-HAE, prevents designing an evidence-based thera-
peutic strategy: development of controlled studies to properly
treat angioedema-related mortality and disability should be
an objective for the future.
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